Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Clinical Oncology

• Publication date

  2006-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2005.03.3332PMID 16648504
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• O-157 Survival benefit of oral topotecan plus supportive care versus supportive care alone in relapsed, resistant SCLC

  2005cited by this paper
• A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer.

  2005cited by this paper
• Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC)

  2005cited by this paper
• Randomized phase II study comparing topotecan/cisplatin administration for 5 days versus 3 days in the treatment of extensive stage small cell lung cancer (SCLC).

  2005cited by this paper
• Topotecan in the treatment of relapsed small cell lung cancer patients with poor performance status.

  2004cited by this paper
• Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer.

  2004cited by this paper
• European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.

  2003cited by this paper
• Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.

  2002cited by this paper
• Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.

  2002cited by this paper
• Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?

  2001cited by this paper
• Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?

  2001cited by this paper
• Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer.

  2001cited by this paper
• Phase II study of oral topotecan (T) with cisplatin (C) in advanced, non-resectable NSCLC. A promising combination

  2000cited by this paper
• A randomized phase III study of irinotecan and cisplatin (CP) versus etoposide and cisplatin (EP) in extensive-disease small-cell lung cancer (ED-SCLC): Japan Clinical Oncology Group Study (JCOG 9511)

  2000cited by this paper
• Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.

  1999cited by this paper
• Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.

  1998cited by this paper
• A dilemma in analysis: issues in the serial measurement of quality of life in patients with advanced lung cancer.

  1997cited by this paper
• Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.

  1992cited by this paper

• Efficacy and tolerability of first-line treatment regimens for extensive-stage small cell lung cancer – a grade-assessed network meta-analysis of randomized controlled trials

  2026cites this paper
• Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): a single-arm phase 2 trial.

  2025cites this paper
• Integrating natural woody composites with modern therapies for enhanced lung cancer treatment

  2024cites this paper
•  A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

  2023cites this paper
• Randomized phase III trial in extended stage small cell lung cancer comparing first line platinum in combination with etoposide or topotecan

  2023cites this paper
• Treatment of drug-induced immune thrombocytopenias

  2022cites this paper
• Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies

  2022cites this paper
• Metastatic Extrapulmonary Small Cell Carcinoma Presenting as Obstructive Jaundice

  2022cites this paper
• Effectiveness and safety of bevacizumab in extensive-disease small cell lung cancer: a systemic review and meta-analysis

  2021cites this paper
• Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma

  2021cites this paper
• Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

  2021cites this paper
• Cáncer de pulmón microcítico

  2021cites this paper
• Update 2021: Management of Small Cell Lung Cancer

  2021cites this paper
• Outcomes of metastatic neuroendocrine carcinoma of the gallbladder

  2021cites this paper
• Topotecan plus Platinum-Based Chemotherapy versus Etoposide plus Platinum-Based Chemotherapy for Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2021cites this paper
• Recent advances in small cell lung cancer: the future is now?

  2020cites this paper
• Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trial

  2020cites this paper
• Systematic evaluation of the efficacy‐effectiveness gap of systemic treatments in extensive disease small cell lung cancer

  2020cites this paper
• Hazard ratio of progression-free survival is an excellent predictor of overall survival in phase III randomized controlled trials evaluating the first-line chemotherapy for extensive-disease small-cell lung cancer

  2020cites this paper
• A systematic review of survival following anti-cancer treatment for small cell lung cancer.

  2020cites this paper
• Cancer of the Lung

  2020cites this paper
• Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?

  2019cites this paper
• Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review.

  2019cites this paper
• Lesser Known Facts of Small Cell Lung Cancer.

  2019cites this paper
• Guideline for the Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-line Chemotherapy.

  2018cites this paper
• Oral hydroxysafflor yellow A reduces obesity in mice by modulating the gut microbiota and serum metabolism

  2018cites this paper
• Chemotherapy for Small Cell Lung Cancer 58

  2018cites this paper
• Chemotherapy for Small Cell Lung Cancer 58

  2018cites this paper
• Home Testing of Blood Counts in Patients with Cancer

  2018cites this paper
• Therapie des kleinzelligen Bronchialkarzinoms

  2018cites this paper
• Efficacy and Safety of Ipilimumab plus Chemotherapy for Advanced Lung Cancer: A Systematic Review and Meta-Analysis

  2018influential citation
• Study of small-cell lung cancer cell-based sensor and its applications in chemotherapy effects rapid evaluation for anticancer drugs.

  2017cites this paper
• Trilaciclib (G1T28): A cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC)—Phase 1b results.

  2017cites this paper
• Molecular modeling of cationic porphyrin-anthraquinone hybrids as DNA topoisomerase IIβ inhibitors

  2017cites this paper
• A systematic review of the quality of statistical methods employed for analysing quality of life data in cancer randomised controlled trials.

  2017cites this paper
• Current Treatments for Surgically Resectable, Limited-Stage, and Extensive-Stage Small Cell Lung Cancer.

  2017cites this paper
• Advances in Small Cell Lung Cancer.

  2017cites this paper
• Small Cell Lung Cancer: Current and Future Strategies

  2016cites this paper
• Mesenchymal stem cells exhibit resistance to topoisomerase inhibition.

  2016cites this paper
• Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells

  2016cites this paper
• Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial

  2016cites this paper
• The Humanistic Burden of Small Cell Lung Cancer (SCLC): A Systematic Review of Health-Related Quality of Life (HRQoL) Literature

  2016influential citation
• Management of Small Cell Lung Cancer: Progress and Updates

  2015cites this paper
• Platinum versus non-platinum chemotherapy regimens for small cell lung cancer.

  2015cites this paper
• Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer

  2015cites this paper
• Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy

  2015cites this paper
• Effect of radiotherapy on the treatment of patients with extensive stage small cell lung cancer.

  2014cites this paper
• Small cell lung cancer: therapies and targets.

  2014cites this paper
• Cancer of the Lung: Non–Small Cell Lung Cancer and Small Cell Lung Cancer

  2014cites this paper
• Health-related quality of life in small-cell lung cancer: a systematic review on reporting of methods and clinical issues in randomised controlled trials.

  2014cites this paper
• Advances in pharmacotherapy of small cell lung cancer

  2014cites this paper
• Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2013cites this paper
• Assessing the relative effectiveness and tolerability of treatments in small cell lung cancer: a network meta-analysis.

  2013cites this paper
• Personalized Management of Lung Cancer

  2013cites this paper
• Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study.

  2013cites this paper
• E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer

  2013cites this paper
• Multimodale Therapie des kleinzelligen Lungenkarzinoms

  2013cites this paper
• Oral delivery of anticancer drugs I: general considerations.

  2013cites this paper
• Small-cell lung cancer: Treatment of extensive-stage disease

  2013cites this paper
• Modulation of regulators of cellular pH in Small Cell Lung Cancer cells by chemotherapeutic drugs

  2013cites this paper
• Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer.

  2013cites this paper
• Chemistry and Biology of Camptothecin and its Derivatives 22

  2013cites this paper
• Cisplatin plus etoposide versus other platin‐based regimens for patients with extensive small‐cell lung cancer: a systematic review and meta‐analysis of randomised, controlled trials

  2012cites this paper
• Modern Management of Small-Cell Lung Cancer

  2012cites this paper
• Treatment of lung cancer.

  2012cites this paper
• Chemotherapy for small cell lung cancer: a comprehensive review

  2012cites this paper
• Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.

  2012cites this paper
• Topotecan/Cisplatin Compared with Cisplatin/Etoposide as First-Line Treatment for Patients with Extensive Disease Small-Cell Lung Cancer: Final Results of a Randomized Phase III Trial

  2012cites this paper
• Role of HGF/MET axis in resistance of lung cancer to contemporary management.

  2012influential citation
• Traitement des cancers bronchiques à petites cellules métastatiques en 2012

  2012cites this paper
• Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer

  2011cites this paper
• Advances in the treatment of small-cell lung cancer.

  2011cites this paper
• Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer

  2011cites this paper
• Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer.

  2011cites this paper
• A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.

  2011cites this paper
• Small cell lung cancer: new clinical recommendations and current status of biomarker assessment.

  2011cites this paper
• Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.

  2011cites this paper
• Therapeutic uses of topotecan for thoracic malignancies

  2011cites this paper
• Current use of Health-Related Quality of Life Outcomes in Advanced-stage Lung Cancer Clinical Trials

  2011cites this paper
• Amélioration de la biodisponibilité orale du docétaxel au moyen de systèmes nanoparticulaires

  2011cites this paper
• Topoisomerase I Inhibitors – The Camptothecins

  2011cites this paper
• Second-line therapy for small-cell lung cancer

  2011cites this paper
• Advances in the Treatment of Small-Cell Lung Cancer

  2011cites this paper
• Small cell lung cancer.

  2011cites this paper
• Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cites this paper
• Treatment options for small cell lung cancer – do we have more choice?

  2010cites this paper
• Treatment of extensive-stage small cell lung carcinoma: current status and future prospects

  2010cites this paper
• A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.

  2010cites this paper
• Phase 2 trial of pemetrexed disodium and carboplatin in previously untreated extensive‐stage small cell lung cancer, N0423

  2010cites this paper
• Small Cell Lung Cancer: Are We Making Progress?

  2010cites this paper
• Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study

  2010cites this paper
• A Phase II Trial of Carboplatin and Weekly Topotecan in the First-Line Treatment of Patients with Extensive Stage Small Cell Lung Cancer

  2010cites this paper
• The value of topotecan in the second-line treatment of small-cell lung cancer. Preliminary report

  2010cites this paper
• [Effect of topotecan as a second line treatment in small cell lung cancer patients. Preliminary report].

  2010cites this paper
• Camptothecins Compared with Etoposide in Combination with Platinum Analog in Extensive Stage Small Cell Lung Cancer: Systematic Review with Meta-Analysis

  2010cites this paper
• Small Cell Carcinoma of the Lung

  2010cites this paper
• 拓扑替康用于小细胞肺癌维持/巩固治疗和挽救治疗的疗效比较

  2010cites this paper
• Small cell lung cancer

  2010cites this paper
• SEOM clinical guidelines for the treatment of small-cell lung cancer

  2010cites this paper
• Therapy of small cell lung cancer with emphasis on oral topotecan.

  2010cites this paper